U.S. markets close in 4 hours 56 minutes
  • S&P 500

    3,621.77
    +44.18 (+1.23%)
     
  • Dow 30

    29,980.88
    +389.61 (+1.32%)
     
  • Nasdaq

    11,984.15
    +103.52 (+0.87%)
     
  • Russell 2000

    1,846.97
    +28.67 (+1.58%)
     
  • Crude Oil

    44.94
    +1.88 (+4.37%)
     
  • Gold

    1,802.30
    -35.50 (-1.93%)
     
  • Silver

    23.16
    -0.47 (-2.00%)
     
  • EUR/USD

    1.1878
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    0.8750
    +0.0180 (+2.10%)
     
  • GBP/USD

    1.3358
    +0.0036 (+0.27%)
     
  • USD/JPY

    104.6520
    +0.1640 (+0.16%)
     
  • BTC-USD

    19,316.91
    +864.95 (+4.69%)
     
  • CMC Crypto 200

    382.29
    +12.54 (+3.39%)
     
  • FTSE 100

    6,414.00
    +80.16 (+1.27%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Epizyme (EPZM) Is Up 10.29% in One Week: What You Should Know

Zacks Equity Research

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Epizyme (EPZM), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Epizyme currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for EPZM that show why this biopharmaceutical company shows promise as a solid momentum pick.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For EPZM, shares are up 10.29% over the past week while the Zacks Medical - Biomedical and Genetics industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 16.05% compares favorably with the industry's 5.27% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Epizyme have increased 58.83% over the past quarter, and have gained 200.17% in the last year. In comparison, the S&P 500 has only moved 5.84% and 21.82%, respectively.

Investors should also take note of EPZM's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, EPZM is averaging 817,072 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with EPZM.

Over the past two months, 7 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost EPZM's consensus estimate, increasing from -$2.22 to -$1.88 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been 1 downward revision in the same time period.

Bottom Line

Given these factors, it shouldn't be surprising that EPZM is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Epizyme on your short list.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Epizyme, Inc. (EPZM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research